Krilogy Financial LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Krilogy Financial LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 12.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 11,893 shares of the company’s stock after purchasing an additional 1,272 shares during the quarter. Krilogy Financial LLC’s holdings in Johnson & Johnson were worth $1,972,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in JNJ. Lantz Financial LLC increased its holdings in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after acquiring an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $453,000. Horan Securities Inc. increased its holdings in Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after acquiring an additional 90 shares in the last quarter. Strategic Financial Concepts LLC increased its holdings in Johnson & Johnson by 57.9% in the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after acquiring an additional 1,271 shares in the last quarter. Finally, State of Wyoming increased its holdings in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after acquiring an additional 10,279 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JNJ. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Bank of America dropped their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Wall Street Zen downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Finally, Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Stock Up 0.2%

NYSE JNJ opened at $156.90 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market capitalization of $377.52 billion, a P/E ratio of 23.59, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a 50 day moving average price of $153.84 and a 200-day moving average price of $153.72.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.